Unicorns Podcast: New low-dose supplement tackles knee pain as joint health market booms

In this episode of The Unicorns Podcast, Justin interviews renowned expert in the field of preventative and personalised health, Dr Brad McEwen PhD.

Australia’s $6.4 billion supplements industry is experiencing a surge in demand for joint health products, driven by an ageing population and a growing focus on mobility. Consumers are seeking non-surgical solutions that offer real functional outcomes, like pain relief and improved movement.

Complementary Medicines Group (CMG) has launched a breakthrough knee product utilising UC-ii, a once-daily collagen-based capsule targeting joint pain and stiffness. Backed by clinical trials, it works by helping the immune system reduce joint inflammation, offering a low-dose alternative to traditional supplements like glucosamine.

Dr Brad McEwen from CMG says the product aligns with rising consumer demand for evidence-based, easy-to-use options in joint health. With the product now available at health stores nationwide, CMG is aiming to lead a new wave of clinically backed mobility supplements in one of the world’s most tightly regulated markets.

This podcast was developed in collaboration with Complementary Medicines Group, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.